193 related articles for article (PubMed ID: 32442299)
1. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
Giri S; Huntington SF; Wang R; Zeidan AM; Podoltsev N; Gore SD; Ma X; Gross CP; Davidoff AJ; Neparidze N
Blood Adv; 2020 May; 4(10):2245-2253. PubMed ID: 32442299
[TBL] [Abstract][Full Text] [Related]
2. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
3. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
[TBL] [Abstract][Full Text] [Related]
4. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
[TBL] [Abstract][Full Text] [Related]
5. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
[TBL] [Abstract][Full Text] [Related]
7. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
Yan J; Zhou DM; Shao XY; Xu Y; Chen B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
[No Abstract] [Full Text] [Related]
8. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Schavgoulidze A; Lauwers-Cances V; Perrot A; Cazaubiel T; Chretien ML; Moreau P; Facon T; Leleu X; Karlin L; Stoppa AM; Decaux O; Belhadj K; Arnulf B; Mohty M; Ariette CM; Fohrer-Sonntag C; Lenain P; Marolleau JP; Tiab M; Araujo C; Orsini-Piocelle F; Jaccard A; Roussel M; Benboubker L; Eveillard JR; Dib M; Divoux M; Attal M; Avet-Loiseau H; Corre J
Haematologica; 2023 May; 108(5):1374-1384. PubMed ID: 36172814
[TBL] [Abstract][Full Text] [Related]
9. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
11. Myc rearrangement redefines the stratification of high-risk multiple myeloma.
Jin X; Li H; Zhang D; Liu S; Song Y; Zhang F; Li Z; Zhuang J
Cancer Med; 2024 Jun; 13(11):e7194. PubMed ID: 38845529
[TBL] [Abstract][Full Text] [Related]
12. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
13. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
Abdallah N; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Rajkumar SV; Kumar SK
Blood Adv; 2020 Aug; 4(15):3509-3519. PubMed ID: 32750129
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
16. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
17. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
20. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
